Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome - IM039-004

Updated: 22 December, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18-65

    Age Range

  • 1

    Location(s)

  • Not Yet Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Part A SAD Dose 1
Biological: BMS-986325
Experimental: Part A SAD Dose 10
Biological: BMS-986325
Experimental: Part A SAD Dose 11 (Optional Arm)
Biological: BMS-986325
Experimental: Part A SAD Dose 2
Biological: BMS-986325
Experimental: Part A SAD Dose 3
Biological: BMS-986325
Experimental: Part A SAD Dose 4
Biological: BMS-986325
Experimental: Part A SAD Dose 5
Biological: BMS-986325
Experimental: Part A SAD Dose 6
Biological: BMS-986325
Experimental: Part A SAD Dose 7
Biological: BMS-986325
Experimental: Part A SAD Dose 8
Biological: BMS-986325
Experimental: Part A SAD Dose 9
Biological: BMS-986325
Placebo Comparator: Part A SAD Placebo 1
Other: Placebo
Placebo Comparator: Part A SAD Placebo 2
Other: Placebo
Experimental: Part B MAD Dose 1
Biological: BMS-986325
Experimental: Part B MAD Dose 2
Biological: BMS-986325
Experimental: Part B MAD Dose 3
Biological: BMS-986325
Placebo Comparator: Part B MAD Placebo
Other: Placebo
Experimental: Part C pSS Dose 1
Biological: BMS-986325
Experimental: Part C pSS Dose 2
Biological: BMS-986325
Experimental: Part C pSS Dose 3 (Optional Arm)
Biological: BMS-986325
Placebo Comparator: Part C pSS Placebo
Other: Placebo

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - BMI: 18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening - Must agree to follow specific methods of contraception, if applicable Healthy Participants (Part A and Part B) - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations - Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening Participants with Sjögren's Syndrome (Part C) - Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS) - Seropositive for anti-Sjögren's syndrome antigen A antibody - Males and females, ages 18, or local age of majority, to 65 years, inclusive at screening Exclusion Criteria: - Woman who are pregnant or breastfeeding - Inability to tolerate venipuncture and/or inadequate venous access Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness - Any other significant medical, psychiatric, and/or social reason as determined by the investigator Participants with Sjögren's Syndrome (Part C) - Systemic immune-mediated disease other than pSS, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjögren's syndrome) - Another immune-mediated disease or inflammatory condition that could interfere with assessment of response of pSS to therapy (e.g., immunoglobulin G4 (IgG4)-related disease, systemic sclerosis, inflammatory bowel disease, gout) - Any other medical condition associated with sicca syndrome (e.g., history of head and neck radiation treatment, diabetes mellitus, sarcoidosis, chronic graft-versus host disease), participants with sicca symptoms secondary to ongoing medication use based on the investigator's assessment Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com